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Summary Hypercalcaemia is an important cause of morbidity in malignant disease. We studied the efficacy and safety of intravenous
ibandronate (a new, potent bisphosphonate) in a multicentre study of 147 patients with severe cancer-associated hypercalcaemia which had
been resistant to treatment with rehydration alone. Of 131 randomized patients who were eligible for evaluation, 45 were allocated to receive
2 mg ibandronate, 44 patients to receive 4 mg and 42 patients to receive 6 mg. Serum calcium values fell progressively in each group from
day 2, reaching a nadir at day 5, and in some patients normocalcaemia was maintained for up to 36 days after treatment. The 2-mg dose was
significantly less effective than the 4-mg or 6-mg dose in correcting hypercalcaemia, as the number of patients who achieved serum calcium
values below 2.7 mm after treatment was 50% in the 2-mg group compared with 75.6% in the 4-mg group and 77.4% in the 6-mg group (P <
0.05; 2 mg vs others). In a logistic regression analysis, three factors were found to predict response; ibandronate dose (higher doses were
more effective), severity of presenting hypercalcaemia (severe hypercalcaemia was associated with less complete response) and tumour
type (patients with breast carcinoma and haematological tumours responded better than those with other tumours). Ibandronate was
generally well tolerated and no serious drug-related adverse events were observed. We conclude that ibandronate is a safe, well tolerated
and effective treatment for cancer-associated hypercalcaemia, which should prove a useful addition to the current range of therapies
available to treat this condition.
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Hypercalcaemia is a common metabolic complication of malig-
nant disease which is associated with substantial morbidity and
mortality (Ralston et al, 1990). The pathophysiology of hypercal-
caemia differs depending on the tumour type, but two broad cate-
gories are recognized (Mundy and Martin, 1982). In humorally
mediated hypercalcaemia, the elevation in blood calcium is most
often caused by release of parathyroid hormone-related protein
(PTHrP), which causes a generalized increase in osteoclastic bone
resorption and increased reabsorption of calcium by the renal
tubule (Yates et al, 1988; Ralston, 1987; Martin and Suva, 1989).
Alternatively, hypercalcaemia may arise as the result of tumour
metastases in bone, which stimulate osteoclastic bone resorption
on a multifocal basis, with release ofcalcium at a rate in excess of
that which can be excreted by the kidney. In both situations,
increased osteoclastic bone resorption plays an important patho-
genic role, providing the rationale for treatment of cancer-associ-
ated hypercalcaemia with inhibitors ofosteoclast activity (Ralston,
1992). Although several inhibitors of osteoclastic bone resorption
have been used in the treatment of cancer-associated hyper-
calcaemia (Mundy et al, 1983; Warrell et al, 1990), bisphospho-
nates have emerged in recent years as a highly effective therapy,
and in the view of many workers are now the treatment of first
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choice (Fleisch, 1991; Body, 1992; Ralston, 1992). Ibandronate
(1-hydroxy-3-(methylpentyl amine) propylidene-bisphosphonate)
is a new bisphosphonate that is approximately 50 times more
potent than pamidronate and 500 times more potent than
clodronate in inhibiting osteoclastic bone resorption in animal
models (Muihlbauer et al, 1991; Fleisch, 1993). Prompted by
preliminary studies which suggested that ibandronate may be of
clinical value in the treatment of tumour-induced hypercalcaemia
(Wuster et al, 1993), the present study was designed to assess
dose-response characteristics in a double-blind randomized
clinical trial.
PATIENTS AND METHODS
The study was a multicentre double-blind randomized comparison
of three doses of intravenous ibandronate in patients with cancer-
associated hypercalcaemia. The study protocol was approved by
all participating local ethics committees with the patients' written
informed consent. Patients with proven malignant disease who had
albumin-corrected serum calcium values of equal to or greater
than 3.0 mm after a minimum of 24 h rehydration with at least 2 1
of intravenous 0.9% saline or a urine output of . 2 1 day -' were
eligible for the study. Calcium values were corrected for albumin
using the formula [Serum total calcium (mM) - (0.02 x albumin
(g 1-') + 0.8)]. Patients were excluded from the study if they
had evidence of significant renal impairment (serum creatinine >
265 ,UM), or had other causes for the hypercalcaemia. Individuals
who had been treated with bisphosphonates during the preceding
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Table 1 Pretreatment characteristics of study group
2mg 4mg 6mg
(rn44) (n=41) (n=40)
Males (n/%) 21 (47%) 19 (46.3%) 18 (45%)
Age (years) range 58.5 64 56
(50.5-66.5) (56-68) (44.5-62)
Serum calciuma 3.43 3.38 3.4
(mM) (3.21-3.65) (3.16-3.88) (3.19-3.63)
[2.2-2.7 mM]
Serum phosphate 0.88 0.90 0.96
(mM) (0.72-1.24) (0.78-1.2) (0.69-1.1)
[0.8-1.4 mM]
Urine Ca/Cr 1.68 1.76 2.07
(mM mm-') (1.23-2.45) (0.91-2.47) (0.89-2.55)
[<0.5]
Serum creatinine 110 100 110
(>M) (80-140) (80-140) (70-150)
[50-120 gM]
Serum PTHrP 2.5 3.0 2.7
(pM) (0.9-6.6) (1.2-8.2) (1.2-6.4)
[<2.6 pM]
Total intravenous 6.0 7.5 7.0
fluids given before (6.0-8.0) (4.6-10.0) (5.0-9.0)
treatment (I)
Total intravenous 12.7 15.0 12.0
fluids given after (5.4-44.0) (8.0-20.5) (6.0-24.0)
treatment (I)
Furosemide treatment (n/%) 23 (53%) 24 (58%) 22 (55%)
Tumour type
Lung 6 (13.6%) 9 (21.9%) 6 (15%)
Breast 12 (27.2%) 14 (34.1%) 12 (30%)
Haematological 2 (4.5%) 4 (9.7%) 6 (15%)
Other 24 (54.5%) 14 (34.1%) 16 (40%)
Bone metastases 26 (59%) 21 (51%) 17 (42.5%)
Values are medians (interquartile range).aAlbumin adjusted. Values in
squared brackets show reference ranges. There was no significant difference
between the groups for any variable at baseline.
3 months, plicamycin during the preceding 4 weeks and cytostatic
drugs or calcitonin during the preceding week of the study were
excluded. Patients who were treated with new cytostatic or anti-
hypercalcaemic therapy after starting the study were censored for
analysis for efficacy from that time on.
A total of 147 patients were enrolled between October 1992 and
February 1994 from 36 centres in eight European countries.
Fifteen patients were excluded during the run-in phase because
serum calcium values fell below 3.0 mm after rehydration, or
because of clinical deterioration or death. One patient who
received treatment without randomization was excluded. The
remaining 131 patients were randomized double blind to receive
2 mg (n=45), 4 mg (n=44) or 6 mg (n=42) ofibandronate by intra-
venous infusion over 2 h in 500 ml of intravenous saline. In order
to ensure that the treatment groups were comparable in terms of
tumour type and severity of hypercalcaemia, stratification for
tumour type and severity of hypercalcaemia after rehydration (<
3.4 mM vs . 3.4 mM) was carried out. Hydration (intravenous or
oral) was continued after ibandronate was administered to achieve
a urine output of approximately 2 1 daily at the discretion of the
attending physician. Treatment with loop diuretics was permitted
only when clinically indicated for reasons of fluid overload or
cardiac failure. Serum levels of calcium, albumin, creatinine,
phosphate, alkaline phosphatase, transaminases and electrolytes
were determined before treatment and at days 3 and 7 and repeated
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Figure 1 Response of hypercalcaemia to intravenous ibandronate. Mean +
s.e.m. of serum calcium adjusted for albumin. Significant change from day 0
is indicated by *P<0.05, **P<0.01 (Wilcoxon test). Significant difference
between 2-mg vs 4-mg and 6-mg groups is indicated by + P<0.05
(Kruskal-Wallis test). Interrupted horizontal line shows upper limit of normal
for adjusted calcium (2.7 mM)
on days 14, 21 and 28. Full blood count was measuredbefore treat-
ment and again at days 7, 14, 21 and 28. Urinary calcium and crea-
tinine were measured on second voided morning urine specimens,
and renal tubular reabsorption was calculated (Nordin et al, 1976).
Serum parathyroid hormone (PTH) and parathyroid hormone-
related protein (PTHrP) concentrations were measured before
treatment and at day 7 by IRMA (Nichols Institute, USA). Bone
metastases were assessed by either radionuclide bone scans or
plain radiographs. All biochemical and haematological investiga-
tions were performed using standard automated techniques.
Patients were continuously assessed for adverse effects. The
primary efficacy evaluation was based on serum-adjusted calcium
levels. A complete response was defined as a serum calcium value
of equal or less than 2.7 mm after treatment. Duration of action
was assessed by two separate analyses: the time in normal range
from response and the time to relapse, defined as an increase of
albumin-corrected serum calcium to 2 3.0 mm in patients who had
an initial response.
Statistical methods used for the evaluation of response rates
were the exact test of Fisher for the comparison of treatment
groups and Kaplan-Meier estimates for duration of response.
Censoring was done in order not to overestimate treatment effects.
Therefore, if, after response and before failure, patients died,
dropped out or received i.v. bisphosphonates orcalcitonin, the data
of these patients were censored at that time. Patients still showing
response at the end of observation were censored at their last
observed trial day. The study was designed to have at least 80%
power for the detection of differences (ax < 5%) in response
rates between the dose groups using a closed-test procedure. In
addition, 95% confidence intervals were calculated using
Pearson-Clopper values. Logistic regression analyses were
performed to determine whether sex, age, weight, baseline serum
calcium, tumour type, presence of bone metastases, serum
PTHrP levels, tubular reabsorption of calcium and the dose of
ibandronate are related to response and to evaluate dose-response
surfaces, which are used for dose recommendation based on those
factors significantly (P<0.05) contributing to response. Further
exploratory analyses were performed using the Kruskal-Wallis
test and the paired Wilcoxon test for comparison between and
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Figure 2 Time from response to relapse of hypercalcaemia after intravenous
ibandronate. Symbols at the bottom of the graph indicate the time points in
each dose group at which patients died or were censored for other reasons
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Figure 3 Dose-response to intravenous ibandronate: normalization of serum
calcium. The columns show the number of patients (as a percentage) in each
dose group whose serum calcium fell below 2.7 mm after treatment. The
black columns refer to data from the 109 patients who survived the first 7
days and the open columns to data from all 125 patients who were evaluated
for efficacy. In both instances, the response was significantly less for the 2-
mg group (P<0.05 from other groups), but did not differ significantly between
the 4-mg and 6-mg groups
within treatment groups respectively. For all analyses, a P-value
< 0.05 was considered as giving evidence of a significant differ-
ence. For all tests performed, a two-sided alternative was assumed.
RESULTS
Seven patients were excluded from analysis after ibandronate
administration because ofprotocol violations (other bisphosphonate
pretreatment, serum calcium < 3.0 mM after rehydration, chemo-
therapy 5 days before treatment with the study drug, change in
chemotherapy 3 weeks before treatment with the study drug, no
sufficient follow-up data available because the patient died 1 day
after the treatment, chemotherapy at start oftreatment with the study
drug, not randomized allocation to treatment), leaving a total of 125
patients evaluable for response. Table I lists the characteristics of
Ibandronate dose (mg)
Figure 4 Response to intravenous ibandronate: effect of tumour type and
severity of hypercalcaemia at presentation. The percentage of patients who
showed a complete response to intravenous ibandronate (serum adjusted
calcium <2.7 mm after treatment) is shown in relation to tumour type and
severity of hypercalcaemia at presentation. The response to ibandronate
tended to be better in patients with breast and haematological cancers (A)
compared with other tumour types (B) at each ibandronate dose. For both
categories of tumour type, patients with more severe hypercalcaemia (Z)
responded significantly less well to ibandronate than those with less severe
hypercalcaemia (-) at each dose
these patients in each of the treatment groups at baseline. The three
dose groups were well matched for age, sex, tumour type, presence
ofbone metastases, severity ofhypercalcaemia and renal function as
judged by serum creatinine values.
Figure 1 shows the response ofserum-adjusted calcium values in
the three treatment groups. Serum calcium fell in response to all
three dose regimens with a nadir at day 5. The response of serum
calcium was similar in patients receiving 4 mg and 6 mg, and both
doses were significantly superior to the 2-mg dose. The median
time in the normal range was 12 days forthe 2- and4-mg doses and
11 days for the 6-mg dose. Although the duration of the trial was
specified to be 31 days, the maximum documented time in normal
range lasted up to 36 days when the investigators stopped
recording. More than 25% of the patients in each treatment group
were in remission from hypercalcaemia at the end of the trial.
Kaplan-Meier analysis (Figure 2) showed that the respective
median time to relapse (defined as a rise in serum albumin-adjusted
calcium to > 3.0 mM) was 18 days in the 4-mg group and 26 days
in the 6-mg group, whereas in the 2-mg group more than 50% of
the patients were still in remission at the end ofthe trial. The dura-
tion of response was not significantly different between the three
treatment groups.
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Figure 5 Predicting response to ibandronate: effect of tumour type, severity
of presenting hypercalcaemia and ibandronate dose. Logistic regression
analysis (the most efficient tool to evaluate the dose-response relationship)
was used to predict the likelihood of a complete response to various doses
of ibandronate, based on severity of hypercalcaemia at presentation and
knowledge of tumour type. For the purpose of this analysis, complete
response was defined as serum-adjusted calcium < 2.7mM after treatment.
The vertical axis shows the likelihood of obtaining a complete response
based on the dose given, severity of hypercalcaemia at presentation and
tumour type. The predicted response in breast and haematological tumours is
shown in A and that of other tumours in B. The analysis clearly demonstrates
the inter-relationship between tumour type, severity of presenting
hypercalcaemia and the response to ibandronate in different doses
Figure 3 compares the effect of the three dose regimens in terms
of those who had a complete response (serum calcium < 2.7 mM),
firstly in all 125 patients evaluated for efficacy and secondly, in
those 109 patients out of the 125 who survived to 7 days. A
complete response was observed in 55.3% of the 109 patients
surviving the first 7 days receiving 2 mg, compared with 75.7%
with 4 mg and 82.3% receiving 6 mg. Corresponding values for
the 125 patients were 50%, 75.6% and 77.5%. In both analyses,
the 4-mg and 6-mg doses did not significantly differ from one
another, but gave a significantly better response than the 2-mg
dose (P<0.05).
The results of the intention-to-treat analysis were almost iden-
tical to the results of the protocol analysis with total response rates
of 50% in the 2-mg dose group, 72.7% in the 4-mg and 76.2% in
the 6-mg dose group.
Figure 4 shows the relationship between tumour type and
severity of presenting hypercalcaemia and the response rate. The
response rate was significantly better in patients with breast carci-
noma and those with haematological tumours (Figure 4A)
compared with all other tumours (Figure 4B) in each dose group.
In general, the response rate in patients with moderate hyper-
calcaemia (calcium 3.0-3.5 mM) was significantly better than
those with severe hypercalcaemia (calcium > 3.5 mM).
In view ofthe differing responses by tumour type and severity of
hypercalcaemia, logistic regression analyses were performed in
order to define the parameters at baseline that were predictive of
response. In these analyses, the response rate was regarded as the
dependent variable and the following as independent variables:
serum calcium pretreatment, tumour type, age, sex, weight, dose,
PTHrP, tubular reabsorption of calcium and presence of bone
metastases. Of all the factors analysed, serum calcium pretreat-
ment, tumour type and ibandronate dose were found to be predic-
tors of response as shown graphically in Figure 5A and B. In this
figure, resulting from the logistic regression model, the estimated
probability of obtaining a complete response (serum calcium < 2.7
mM) is shown on the y-axis, in relation to baseline serum calcium
(x-axis) and ibandronate dose (z-axis), in the subgroups ofpatients
with breast and haematological tumours (Figure SA) and those
with all other tumours (Figure 5B). From this analysis, it is
possible to choose the dose of ibandronate most likely to give a
complete response, based on knowledge of the tumour type and
serum calcium pretreatment. For example, in patients with breast
orhaematological tumours with serum calcium < 3.0 mm, a dose of
2 mg is equally as likely to give a complete response as 4 mg or 6
mg, whereas 4 mg is required for an optimal response with calcium
values up to 3.5 mm and 6 mg for calcium values above 3.5 mM.
Conversely, in patients with humoral hypercalcaemia in other solid
tumours, 6 mg is required for serum calcium values > 3.0 mM.
Ibandronate was generally well tolerated. Although there was a
high incidence of adverse events in the study group as a whole,
reflecting the serious nature ofthe underlying pathology, there was
no significant difference between the three treatment groups in the
number ortype ofrecorded adverse events: 2 mg, 133 events; 4 mg,
117 events; 6 mg, 104 adverse events. Fever was observed in 27
patients overall (21.6%), although in most cases this was attribut-
able to coexisting septic events, such as chest or urinary infections.
Only 17 (12.9%) patients had fever reported that was otherwise
unexplained and, hence, potentially attributable to ibandronate
therapy and for which no dose dependency was discernible. There
were no injection site reactions, but asymptomatic hypocalcaemia
was observed in six patients. Two episodes of hypocalcaemia were
reported in the group who received 4 mg and four in the group who
received 6 mg. The higher incidence of hypocalcaemia in patients
who received higher doses would be consistent with a drug-related
effect. About 70% of all patients developed asymptomatic hypo-
phosphataemia, which was considered clinically irrelevant and
required no treatment. In these end-stage tumour patients, the eval-
uated kidney, liver and haematological laboratory parameters gave
no hints oftoxicity attributable to the test drug.
DISCUSSION
As in a previous study (Wuster et al, 1993), we found ibandronate
to be an effective and well-tolerated treatment ofcancer-associated
hypercalcaemia. The response to ibandronate was clearly dose
related and, overall, the 2-mg dose was significantly less effective
than 4 mg or 6 mg in restoring normocalcaemia. Other factors that
contributed to the response were tumour type and severity of
hypercalcaemia at presentation. The response in patients with
breast carcinoma and haematological tumours was significantly
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better than in those with other tumours. These effects are likely to
relate to the underlying mechanisms of hypercalcaemia, which
would be expected to be predominantly local osteolytic in the
group with haematological tumours (Ralston, 1991), mixed in
those with breast tumours (Percival et al, 1985; Isales et al, 1987;
Gallacher et al, 1990; Grill et al, 1991) and predominantly humoral
in the other solid tumour types (Ralston, 1991; Martin and Suva,
1989). These findings concur with the experience of several
previous investigators who have found that patients with humoral
hypercalcaemia are more resistant to the effects of bisphospho-
nates (Ralston et al, 1987; Gurney et al, 1989), probably because
of PTHrP-mediated increases in renal tubular reabsorption of
calcium, which is unaffected by inhibitors of osteoclastic bone
resorption (Ralston et al, 1987; Bonjouret al, 1988; Thiebaud et al,
1990). The second major factor in predicting response was
severity of hypercalcaemia at presentation. This again has been
noted by previous investigators (Body et al, 1987; Gurney et al,
1989; Nussbaum et al, 1993a; Body and Dumon, 1994) and
suggests that patients with more severe hypercalcaemia have more
aggressive bone resorption and/or greater increases in renal tubular
calcium reabsorption, which is more difficult to control with
bisphosphonate therapy.
The inter-relationship between these three factors in deter-
mining response was demonstrated by logistic regression analysis,
which identified ibandronate dose, tumour type and severity of
presenting hypercalcaemia as the most important predictors of
response. From this analysis, we were able to give an indication of
the ibandronate dose most likely to be effective in restoring
normocalcaemia, based simply on the knowledge of tumour type
and severity of hypercalcaemia at presentation. Using this knowl-
edge, it should be possible to tailor the dose on an individual basis
in clinical practice, with practical advantages in terms of cost and
high predictability of individual response to treatment. Further-
more, the response to the dose of 2 mg in hypercalcaemic patients
with baseline serum calcium < 3.0 mM gives the first indication
that this dose may well be used in patients with metastatic bone
disease.
The overall response to ibandronate compares favourably with
that ofother bisphosphonates (Ralston et al, 1989; Nussbaum et al,
1993a; O'Rourke et al, 1993) and gallium nitrate (Warrell et al,
1984), all of which have been used successfully in the treatment
of tumour-induced hypercalcaemia. While the data presented here
suggest that ibandronate may have similar efficacy and duration
of action to pamidronate and alendronate and a longer duration
of action than etidronate and clodronate (Ralston et al, 1989;
O'Rourke et al, 1993), direct comparative trials of these agents
would need to be performed before this can be confirmed, since
differences in patient selection, mix of tumour types and severity
of presenting hypercalcaemia can lead to major differences in the
response observed, as demonstrated by the experience of previous
workers (Thiebaud et al, 1986; Nussbaum et al, 1993b) and by the
logistic regression analysis performed in this study.
The good tolerance, low incidence of fever, coupled with the
short infusion time of 2 h (or even less in the future), which
compares favourably with previously described aminobisphospho-
nates, identifies a single intravenous infusion of ibandronate as an
effective and well-tolerated treatment for cancer-associated hyper-
calcaemia. The following dosages can be recommended for clin-
ical use: in patients with serum calcium <3.0 mm, a dose of2 mg is
recommended as it is equally as likely to give a complete response
as 4 mg or 6 mg, while 4 mg should be used initially for serum
calcium values above 3.0 mm. As the total dose of 6 mg might
further increase the response and duration of action, this dose
should be considered in some cases of severe hypercalcaemia
and those in which the hypercalcaemia is suspected to be of
humoral origin.
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